Skip to main content
Fig. 3 | BMC Urology

Fig. 3

From: A retrospective study of treatment persistence and adherence to α-blocker plus antimuscarinic combination therapies, in men with LUTS/BPH in the Netherlands

Fig. 3

Median time to discontinuation according to polypharmacy‡ (a) and age (years) at index date (b) for all men who received an α-blocker plus antimuscarinic combination therapy (FDC or concomitant therapy). ‡Number of drugs (classified by Anatomical Therapeutic Chemical code) prescribed, excluding those approved for the treatment of LUTS/BPH. FDC: fixed-dose combination; LUTS/BPH: lower urinary tract symptoms associated with benign prostatic hyperplasia

Back to article page

BMC Urology

ISSN: 1471-2490

Contact us